Skip to content

The elucidation for the modulation of endogenous pain inhibitory mechanism by drugs for the treatment of neuropathic pain

The elucidation for the modulation of endogenous pain inhibitory mechanism by drugs for the treatment of neuropathic pain - The elucidation for the modulation of endogenous pain inhibitory mechanism by drugs for the treatment of neuropathic pain

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000053700
Enrollment
50
Registered
2024-02-25
Start date
2024-02-26
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy volunteers

Interventions

Oral administration of pregabalin 150 mg, mirogabalin 15 mg, duloxetine 60 mg, amitriptyline 75 mg, vaccinia virus-inoculated rabbit inflamed skin extract 8 units, or lactose hydrate 2 tablets (contro

Sponsors

Division of Dental Anesthesiology, Department of Diagnostic and Therapeutic Sciences, Meikai University School of Dentistry
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: after informed consent is obtained, over 18 years old, healthy volunteers

Exclusion criteria

Exclusion criteria: the inability to give informed consent, under 18 years old, patients with a history of hypersensitivity to any of these ingredients, which is a contraindication to the administration of drugs of pregabalin, myrogabalin, duloxetine, amitriptyline, or vaccinia virus inoculated rabbit inflammatory skin extract, patients on monoamine oxidase (MAO) inhibitors or within 2 weeks of discontinuation of MAO inhibitors, patients with severe hepatic dysfunction, angle-closure glaucoma, early recovery from myocardial infarction, or urinary retention (prostate disease, etc.), requiring caution in administration, acute intoxication with alcohol, sleeping pills, analgesics, opioid analgesics or psychotropic drugs, within 1 week after receiving or discontinuing nalmefene hydrochloride hydrate, epilepsy not adequately controlled by treatment, renal dysfunction, severe congestive heart failure, elderly patients, history of angioedema, tendency or history of drug dependence, psychiatric disorders, pregnant women, and nursing mothers

Design outcomes

Primary

MeasureTime frame
The evaluation of CPM effect before and after oral medication of the drugs for neuropathic pain. CPM effect is evaluated by pressure pain threshold (PPT) before and during conditioning stimulus.

Secondary

MeasureTime frame
the modulation of QST (the Thermal Pain Illusion(TPI), Temporal Summation(TS), Offset Analgesia(OA) etc) and the effect of background (for example, psychology test including SDS, STAI, PCS etc), and the stress evaluated by catecholamine concentrations in plasma, urine and sweat.

Countries

Japan

Contacts

Public ContactYuka Oono

Department of Diagnostic and Therapeutic Sciences, School of Dentistry, Meikai University Division of Dental Anesthesiology

yoono@dent.meikai.ac.jp049-279-2738

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026